Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease
Algorithm-based Management to Reduce the Recurrence of Gastrointestinal Bleeding and Severe Epistaxis in Von Willebrand Disease: WILL-MANAGE Trial
University Hospital, Lille
66 participants
Mar 10, 2026
INTERVENTIONAL
Conditions
Summary
WILL MANAGE is a prospective multicenter controlled open label randomized trial comparing an algorithm-based multidisciplinary management to a standard of care to reduce the incidence of bleeding (GI bleeding or severe epistaxis) recurrence in von Willebrand disease.
Eligibility
Inclusion Criteria5
- Males and females adults aged > 18 years
- With a constitutional von Willebrand Disease (according to the phenotypic criteria of the French Reference Center of von Willebrand Disease)
- With a GI bleeding \[either overt (any hematemesis, any melena or hematochezia with at least a 2g/dL drop in hemoglobin) or occult (iron deficiency anemia with at least 2g/dL drop in hemoglobin)\] with the presence of angiodysplasia or a negative finding on digestive conventional endoscopy OR with a severe epistaxis (requiring red blood cells transfusion or treatment with VWF concentrates)
- Be affiliated to a social security scheme
- Written informed consent obtained
Exclusion Criteria10
- Acquired von Willebrand Disease
- Presence of an inhibitor to VWF or a contra indication to VWF concentrates
- Contra-indication to videocapsule endoscopy
- Refusal of the procedures part of the study
- Pregnant women or breastfeeding
- Short-life expectancy
- Liver cirrhosis Child-Pugh C or diagnosed portal hypertension
- Cancer currently undergoing chemotherapy
- Inability to provide informed consent
- Patient under justice protection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
systematic gastrointestinal and nasal endoscopic exploration, local endoscopic treatment whenever applicable,prophylaxis with stepwise dose escalation of VWF concentrate and use of antiangiogenic drugs in patients with severe GI angiodysplasia-related bleeding
Standard of care management
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06651255